The Atia Vision IOL demonstrates the potential to achieve predictable refractive outcomes approaching plano, while simultaneously offering functional distance-corrected intermediate (DCIVA) and distance-corrected near visual acuities (DCNVA), according to early clinical trial outcomes presented at ASCRS 2023.
The prospective clinical trial, currently underway, is a 12-month study conducted in a non-randomized, open-label fashion. The dual-optic IOL system consists of a shape-changing, fluid-filled accommodating base and a fixed power front optic. The design enables the IOL to adjust its power according to the natural accommodative demand of the eye, resulting in dynamic power change.
The study enrolled patients ≥50 years with visually significant cataracts. The surgical procedure involved a sutureless corneal incision of 3.5 mm. Visual acuities were measured before surgery and at 1, 3, 6, and 12 months post-surgery, including best corrected distance (BCDVA), distance-corrected intermediate (DCIVA), and distance-corrected near visual acuities (DCNVA). Defocus curves were also assessed. Throughout the study duration, safety and patient satisfaction were closely monitored.
Preliminary findings from the 3-month data of 13 monocular cases are promising, with 89% of patients exhibiting stable refraction within ±0.5D of plano. The mean monocular BCDVA was -0.02 (±0.07) logMAR (20/19), indicating exceptional visual acuity. DCIVA was measured at 0.01 (±0.10) logMAR (20/20), while DCNVA was recorded at 0.22 (±0.11) logMAR (20/33). The mean defocus curve demonstrated visual acuity better than 20/32 across the range of 0 to -1.5D. Notably, the study’s patients-directed symptom assessment revealed only 1 case of positive dysphotopsia.
Reference
Waring GO, et al. Prospective, Open-Label, Non-Randomized, Trial of a Presbyopia-Correcting, Modular Intraocular Lens System for Treatment of Cataract. Presented at: ASCRS 2023.
Related Content
